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Sarcoidosis is characterised by increased inlammatory activity within tissue granulomata, with accumulation of 
activated lymphocytes and monocyte-derived macrophages (epithelioid macrophages) and local release of proin-
lammatory cytokines1–3. Lung macrophages, derived from blood monocytes4, are potent producers of TNF and 
IL-65–7 which contribute to the formation of sarcoid granulomata8.
Regulation of inlammatory responses is vital to initiate resolution and prevent excessive tissue damage9. 
Abnormalities of regulatory pathways that normally act to dampen inlammation could explain the hyper-active 
immunological state seen in sarcoidosis. Interleukin-10 (IL-10) is the archetypal regulatory cytokine involved in 
control of h1 immune activity. IL-10 is produced primarily by monocytes and regulatory T lymphocytes, and 
acts through its receptor IL-10R on T cells, monocytes, and macrophages10. Cranshaw et al. reported that sar-
coidosis blood monocytes produced smaller amounts of IL-10 than controls and were less able to suppress T cell 
proliferation11. Monocytes and macrophages also express signal-regulatory protein-alpha (SIRP-α) which binds 
to ubiquitously expressed CD47 and acts as an anti-phagocytic signal12, and CD200R13, which binds its cognate 
ligand CD200L on many cell types and leads to reduced mitogen-activated protein kinase signalling through 
recruitment of Ras GTPase activating protein14. he CD200R/CD200L axis is vital in maintaining immune home-
ostasis in the lungs of mice14,15, and reduced CD200R signalling has been implicated in the pathology of joint 
inlammation16, neurodegeneration17, and cancer18.
he aim of the present study was to assess the role of regulatory receptors in modulating monocyte cytokine 
production in sarcoidosis. A whole blood assay was chosen for monocyte stimulation to minimise ex vivo pertur-
bation of monocytes. Monocytes are shown to be a source of TNF and IL-6 within stimulated whole blood assays, 
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and monocytes from sarcoidosis patients produced these cytokines to a greater extent than healthy volunteers. 
Patients with sarcoidosis more commonly had monocytes expressing low levels of CD200R, whereas other regu-
latory receptors (IL-10R, SIRP-α) were expressed at normal levels. Finally, blockade of CD200R or CD200L led 
to increased production of TNF and IL-6. Collectively, the data argue that reduced expression of CD200R is an 
important mechanism underlying monocyte/macrophage hyper-responsiveness in sarcoidosis.

Ǥ he demographics and clinical details of study 
participants are shown in Table 1. All subjects were Caucasians. Patients with sarcoidosis were all non-smokers 
and were not taking corticosteroids or other disease modifying therapies. Twelve subjects with sarcoidosis (40%) 
had a Scadding stage 0 or 1 chest X-ray (i.e. without visible lung changes) and 18 (60%) had a stage 2 or 3 chest 
X-ray. All subjects had CT scan evidence of lung parenchymal abnormalities or mediastinal lymph node enlarge-
ment. Immunophenotyping of PBMCs showed that patients with sarcoidosis exhibited a general T lymphocyto-
penia, in keeping with previous reports19 (Supplementary Table S3 and Supplementary Fig. S1).
	Ǧ ?Ǥ A whole blood assay was used for ex vivo stimu-
lation studies. Signiicantly higher concentrations of secreted TNF and IL-6 were found in stimulated whole blood 
from patients with sarcoidosis compared with healthy controls (Fig. 1). IFNγ and IL-10 were not signiicantly 
diferent between sarcoidosis patients and healthy controls (Fig. 1). When the kinetics of cytokine production 
in PHA-stimulated whole blood were measured, IFNγ and IL-10 were produced with kinetics commensurate 
with T lymphocyte activation, whereas TNF production was rapid, peaking at 3–6 hours and declining thereater 
(Supplementary Fig. S2). Similar kinetics have been observed by others for monocyte-derived TNF20,21. PHA is 
a T cell mitogen22 and it also stimulates monocytes by cross-linking Toll-like receptors23. To further explore the 
relative contribution of T lymphocytes and monocytes to the enhanced cytokine release observed in sarcoidosis, 
whole blood was stimulated with SEA, a more selective T cell mitogen. IL-6 production in response to SEA was 
signiicantly lower in blood from sarcoidosis patients (Fig. 2), consistent with the T lymphocytopenia.
To conirm that monocytes were responsible for the enhanced TNF and IL-6 production observed in sar-
coidosis patients following PHA stimulation, intracellular accumulation of TNF was quantified by flow 
cytometry in Brefeldin A-treated PBMCs. PHA led to a substantial accumulation of TNF in monocytes, but 
not lymphocytes (Fig. 3). In sarcoidosis monocytes, stimulated intracellular TNF accumulation was signii-
cantly greater than in healthy controls (Fig. 3). More IL-6 accumulation was also seen in sarcoidosis monocytes 
(Supplementary Fig. S3).
Ǥ Monocytes appeared to be responsible 
for elevated TNF and IL-6 responses in sarcoidosis patients, so monocyte subsets were characterised based on 
relative expression of CD14 and CD1624. In sarcoidosis patients there was expansion of the intermediate CD14++/
CD16+ monocyte population (13.6% ± 1.01 (mean ± SEM) compared with 9.3% ± 0.82, p < 0.05) and reduction 
in classical CD14++/CD16− monocytes (78.1% ± 1.13 compared with 83.6% ± 2.01, p < 0.01) (Fig. 4). here was 
no signiicant diference in non-classical CD14+/CD16++ monocytes between the cohorts (7.9% ± 1.51 compared 
with 7.1% ± 0.76).
    ? ? ?  Ǥ Monocyte- and 
macrophage-derived TNF can be regulated by a variety of cytokines and cell surface receptor-ligand interactions15. 
herefore, IL-10R, SIRP-α, and CD200R on monocytes were examined to determine whether expression of these 
receptors was altered in patients with sarcoidosis. Expression proiles of IL-10R and SIRP-α/β were similar 
in sarcoidosis patients and healthy controls (Fig. 5). Similarly, expression of CD47, the ligand for SIRP-α/β, 
was the same in sarcoidosis and controls (data not shown).
Category Healthy Sarcoidosis
Number 31 30
Age (years) 41 (20–72) 51 (28–73)
Male/female 13/18 16/14
Scadding chest x-ray stage (%)
—
0 7
1 33
2 43
3 17
Serum ACE activity  
(reference range 8–65 U/L)
— 84.5 (25–356)
C-reactive protein  
(reference range 0–8 mg/L)
— 3.8 (0.5–64)
Plasma viscosity  
(reference range 1.5–1.72 m.Pas.s)
— 1.68 (1.49–1.93)
Table 1.  Demographics and clinical data for healthy subjects and patients with sarcoidosis. Data are 
presented as median (range).
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In contrast, CD200R expression on blood monocytes from patients with sarcoidosis was reduced, with 
patients clustering as high or low expressers (p < 0.05) (Fig. 6). Using a boundary deining low expression below 
the standard deviation of the healthy population (geometric mean < 7.28 luorescence units), 52.9% of sarcoidosis 
patients were classiied as CD200Rlow compared with 11.7% of healthy donors (P < 0.0001) (Fig. 6). Monocyte 
CD200R expression was not related to serum ACE activity, C-reactive protein, or plasma viscosity (data not 
shown). CD200R expression on T lymphocytes in sarcoidosis also polarised as either CD200Rlow or CD200Rhigh 
in a bimodal distribution, compared with a unimodal distribution in healthy controls (Fig. S4).
Expression of the ligand CD200L was absent on monocytes, and the percentage of CD200L+ T lymphocytes 
was similar in sarcoidosis patients and healthy subjects (data not shown). However, because of the T cell lym-
phocytopenia there were fewer T cells expressing CD200L in sarcoidosis blood (0.16 ± 0.03 × 106 compared with 
0.39 ± 0.03 × 106 cells/ml, p < 0.0001).
 ? ? ?Ȁ ? ? ?	Ǧ ?Ǥ To investigate how CD200L/
CD200R interactions regulate proinlammatory cytokine release, monocyte CD200R expression was correlated 
with stimulated cytokine release in whole blood assays and PBMC cultures. In sarcoidosis, IL-6 responses were 
signiicantly higher in subjects with low monocyte CD200R expression when compared with high CD200R 
expressers (Fig. 6), and a similar trend was observed for TNF. When data from sarcoidosis and healthy subjects 
were pooled there was a trend towards an inverse correlation between IL-6 release and monocyte CD200R expres-
sion (r = 0.39, p = 0.21) (Fig. 6).
To determine whether the CD200L/CD200R axis was important for regulating cytokine production in whole 
blood, blocking studies were performed using antibodies. CD200R blockade increased cytokine release from 
isolated PBMCs from healthy subjects (Fig. 7). TNF increased by 35.7 ± 29.2% (mean ± SEM; mean diference 
1282 ± 427 pg/ml, P = 0.04), and IL-6 increased by 22.3 ± 19.4% (mean diference 14430 ± 8369 pg/ml, P = 0.16). 
Similarly, CD200L blockade in whole blood increased TNF and IL-6 release. TNF increased by 14.5 ± 7.4% (mean 
diference of 292 ± 93.6 pg/ml, P = 0.026) and IL-6 increased by 6.9 ± 3.1% (mean diference 8366 ± 3078 pg/ml, 
P = 0.042) (Fig. 7).
Figure 1. TNF and IL-6 release from PHA-stimulated whole blood is greater in patients with sarcoidosis 
than healthy controls. Whole blood was stimulated with phytohaemagglutinin (PHA) 0.1–100 µg/ml. (a) IL-6 
(n = 17), (b) TNF (n = 14), (c) IFN-γ (n = 21), and (d) IL-10 (n = 17) were measured ater 16 hours. Results are 
presented as mean ± SEM; *p < 0.05, **p < 0.001 using two-way ANOVA with Sidak’s post hoc test.
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Discussion
his study is the irst to characterise the expression of the regulatory receptor CD200R and its ligand CD200L 
on blood mononuclear cells in sarcoidosis. We have demonstrated that the distribution of monocyte CD200R 
expression in a cohort of patients with sarcoidosis is distinctly diferent from healthy control subjects, with a sig-
niicantly higher proportion of sarcoidosis patients exhibiting a CD200Rlow monocyte phenotype. Low monocyte 
CD200R expression was associated with heightened TNF and IL-6 production in response to PHA stimulation, 
and blockade of CD200R or CD200L in healthy controls led to increased TNF and IL-6 secretion by monocytes, 
recapitulating the hyper-activated monocyte state seen in sarcoidosis.
Monocyte CD200R expression was not associated with serum ACE activity, suggesting that CD200R is not 
simply a marker of total granuloma burden25. Other studies have reported reduced CD200R expression on 
monocytes in inlammatory arthritis16. However, CD200R expression in sarcoidosis did not correlate with serum 
C-reactive protein or plasma viscosity, signifying that a CD200Rlow monocyte phenotype is not a manifesta-
tion of systemic inlammation. hus monocyte CD200R appears to relect a unique aspect of disease activity 
in sarcoidosis. Further studies are required to assess its value in predicting disease progression and response 
to anti-inlammatory therapy. Whether a similar hyper-responsive phenotype is exhibited by local tissue mac-
rophages in sarcoidosis has yet to be determined; responses in peripheral blood monocytes may not translate 
directly to the macrophages within granulomata. Murine models suggest that in lung inlammation, monocytes 
actively contribute to resident macrophage populations4. Lung macrophages are potent producers of TNF and 
IL-65,6 which contribute to the formation of sarcoid granulomata8.
Despite the evidence for active cellular immunity within tissue granulomata, previous research on peripheral 
blood in sarcoidosis has been subject to contradictory reports suggesting immune responses may be enhanced26,27, 
diminished28,29 or similar to healthy populations30. Reports of suppressed peripheral blood T lymphocyte 
responses and skin test anergy to speciic antigens and non-speciic mitogens may be explained by reduced CD4+ 
T helper cells or increased regulatory T cells. In the present study, patients with sarcoidosis displayed a reduced 
Figure 2. IL-6 release from SEA-stimulated whole blood is reduced in patients with sarcoidosis. Whole 
blood was stimulated with staphylococcus enterotoxin A (SEA) 0.1–10 µg/ml. (a) IL-6 (n = 7–8), (b) TNF 
(n = 6–10), (c) IFN-γ (n = 7), and (d) IL-10 (n = 5–6) were measured ater 16 hours. Results are presented as 
mean ± SEM; ***P < 0.0001 using two-way ANOVA with Sidak’s post hoc test.
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peripheral blood immune response when T lymphocytes are selectively stimulated with SEA, consistent with the 
observed T lymphocytopenia. he increased responsiveness to PHA in sarcoidosis patients was observed par-
ticularly at higher concentrations of stimulant, which would be consistent with a dose-dependent model where 
regulation over a speciic threshold is reduced.
The present study implicates blood monocytes as potentially important regulatory cells in sarcoidosis. 
Cranshaw et al. reported that sarcoidosis monocytes had reduced IL-10 production11. In the whole blood assay 
used in the present study, we did not demonstrate that the IL-10 regulatory axis was dysfunctional in sarcoido-
sis, and the expression proiles of regulatory SIRP-α/CD47 were also similar between sarcoidosis and healthy 
subjects. he choice of methods for cell isolation and stimulation could explain the diferences in the indings, 
since Cranshaw et al. studied monocytes that had been isolated by magnetic bead negative selection and stimu-
lated with lipopolysaccharide11. Depending on the nature of the stimulant or other factors, deiciencies in more 
than one monocyte regulatory pathway may contribute to immune hyper-activation in sarcoidosis. We also 
demonstrated that in patients with sarcoidosis the intermediate CD16+ CD14++ blood monocyte population was 
expanded. Since this monocyte subset has been shown to express the highest levels of the TNF receptor TNFR131, 
monocytes in sarcoidosis may be more responsive to TNF.
Although the whole blood assay used in the present study has an advantage in minimally perturbing cells 
such as monocytes that are highly pleiotropic and respond rapidly to changing environments on isolation and in 
tissue culture, the assay does have some limitations. For example, due to T cell lymphocytopenia, fewer CD200L+ 
lymphocytes will be present in sarcoidosis blood for potential ligation of monocyte CD200R.
Anti-inlammatory drug treatment in sarcoidosis is generally considered to be clinically indicated if, fol-
lowing an initial observation period, there is evidence of progressive disease. Corticosteroid treatment reduces 
macrophage TNF release and leads to improvement in disease markers, but the efect of steroids on long term 
Figure 3. TNF production by monocytes is increased in sarcoidosis. Representative low cytometry 
histograms showing intracellular TNF accumulation in (a) monocytes and (b) lymphocytes ater incubation 
with PHA for 16 hours. Dark grey line, unstimulated isotype control antibody; light grey, unstimulated TNF; 
solid black, PHA stimulated TNF. x axis, TNF luorescence intensity; y axis, number of events. (c) Intracellular 
TNF accumulation in monocytes in response to 10 µg/ml PHA in patients with sarcoidosis and controls (n = 3). 
Results are presented as mean ± SEM geometric mean luorescence intensity; *p < 0.05, **p < 0.01 using two-
way ANOVA with Bonferroni’s post hoc test.
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outcomes is uncertain and the beneits have to be balanced against the potential for serious side efects32,33. 
TNF-blocking biological therapies have been tested, with mixed results. Treatment with the TNF monoclonal 
antibody inliximab reduced tissue inlammation as measured by 18F-luorodeoxyglucose uptake on positron 
emission tomography imaging in an open label study34, and led to a small (2.5%) improvement in FVC at 24 
weeks compared with placebo in patients with chronic pulmonary sarcoidosis in a randomised controlled trial35. 
Conversely, studies with TNF-blocking protein etanercept showed high treatment failure rates36, and anti-TNF 
therapy for rheumatic diseases has been linked in many reports to de novo development of sarcoidosis-like gran-
ulomata37. hese indings indicate that therapeutic TNF blockade in sarcoidosis is not a panacea. Alternatively, 
CD200R is potentially targetable as an anti-inlammatory therapeutic strategy. CD200 recombinant proteins and 
agonistic antibodies have been reported to reduce macrophage activation and promote immunological tolerance 
in human cells in vitro and in mice in vivo38–41.
he present study provides evidence that the CD200R/CD200L axis is important in modulating proinlam-
matory cytokine release from monocytes in sarcoidosis, and raises the possibility that disease progression could 
be propagated by reduced monocyte CD200R expression. here is a need for improved treatment options for 
patients with sarcoidosis, and the CD200L/CD200R axis is potentially tractable for future therapy42.

Ǥ Ethical approval for the use of blood samples from healthy volunteers was obtained from the Ethics 
Committee, Hull York Medical School. Regional ethical approval was obtained to obtain blood and tissue samples 
Figure 4. Intermediate CD14++ CD16+ blood monocytes are expanded in sarcoidosis. Representative two 
colour low cytometry dot pots from (a) control and (b) sarcoidosis subjects with intermediate monocytes 
indicated (int). Monocyte subsets were determined by extracellular antibody staining for CD14 and CD16. 
(c) Percentages of CD14++ CD16+ intermediate monocytes, CD14++ CD16− classical monocytes, and CD14+ 
CD16++ non-classical monocytes in patients with sarcoidosis (n = 14) and controls (n = 18). Results are 
presented as mean ± SEM; *p < 0.05, **p < 0.01 using two-way ANOVA with Sidak’s Post hoc test.
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from sarcoidosis patients from the Hull and East Riding local research ethics committee (LREC 08/H1304/54). 
Written informed consent was obtained from all subjects, and all methods were performed in accordance with 
the relevant guidelines and regulations of Good Clinical Practice. Patients with sarcoidosis were diagnosed by 
multi-disciplinary assessment and displayed non-caseating granulomata on histopathological analysis. Patients 
with other granulomatous diseases were excluded. Exclusion criteria for sarcoidosis patients and healthy vol-
unteers were concomitant inlammatory or immunological diseases, treatment with corticosteroids or other 
immune-modulatory therapies, and current tobacco smoking. Blood was collected in sodium heparin tubes (BD) 
and processed within 1 hour. he results of each set of experiments informed subsequent experimental protocols 
so not all patients and controls contributed to all of the experiments. To avoid bias, subjects included in each set 
of experiments were not selected in any way. he numbers of subjects contributing to each experiment are shown 
in the igure legends.
Ǥ See Supplementary Tables S1 and S2.
ȋȌǤ Heparinised whole blood was diluted 1:1 with 
sterile phosphate-bufered saline (PBS) and layered over Histopaque 1077 in a 1:1 ratio. he gradient was centri-
fuged at 600 × g for 30 minutes without braking. he PBMC layer was removed with a sterile pipette and washed 
twice before suspending in RPMI medium. Whole blood or isolated PBMCs were incubated at 37 °C in a 5% CO2 
atmosphere.
Ǥ Phytohaemagglutinin (PHA) or Staphylococcus aureus enterotoxin 
A (SEA) were added to 1 ml aliquots of fresh whole blood in microfuge tubes and incubated at 37 °C for 16 hrs 
(1–72 hrs for time course experiments). Following centrifugation at 3000 × g for 8 minutes, plasma was collected 
and stored at −20 °C. Isolated PBMCs were resuspended in the same volume of RPMI media as the original blood 
volume and incubated under the same conditions as whole blood. ELISA kits (Biolegend, San Diego, USA) were 
used to measure IFN-γ, IL-10, TNF, IL-6, IL-4 and IL-12(p70) according to the manufacturer’s instructions. Plates 
were analysed using a Multiskan FC Microplate Photometer (hermo Scientiic, Waltham, USA). Results below 
the minimum detectable limits with 1:2 dilutions of plasma were recorded as zero.
Figure 5. SIRP-α and IL-10R expression is similar in sarcoidosis patients and controls. (a) Representative 
low cytometry dot plots showing SIRP-α/β expression on monocytes in a healthy control subject and a patient 
with sarcoidosis. (b) Expression of SIRP-α/β and IL-10R on monocytes and T lymphocytes in sarcoidosis 
patients (n = 9) compared with controls (n = 10). Results are presented as mean ± SEM geometric mean 
luorescence intensity; P = NS using Mann-Whitney U test.
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Figure 6. CD200R expression on monocytes is reduced in sarcoidosis, and CD200Rlow phenotype is 
associated with increased proinlammatory cytokine release. (a) Representative low cytometry histograms 
showing CD200R expression on monocytes from a patient with sarcoidosis and a healthy control subject. Grey 
dotted line, isotype control antibody in healthy control; black dashed line, isotype control in sarcoidosis; grey 
solid line, CD200R healthy; black solid line, CD200R sarcoidosis. x axis, CD200R luorescence intensity; y 
axis, number of events. (b) CD200R expression on monocytes in sarcoidosis and control subjects. Medians are 
indicated by horizontal lines; *p < 0.05 using the Kolmogorov–Smirnov test; n = 17 healthy controls, n = 17 
sarcoidosis patients. (c) Relationship between monocyte CD200R expression and whole blood IL-6 release in 
response to stimulation with 100 µg PHA. Black line, sarcoidosis linear regression (n = 13); grey line, control 
linear regression (n = 10). (d) Stimulated IL-6 release in CD200Rlow (n = 8) and CD200Rhigh (n = 15) pooled 
subjects; *p = 0.018 using Student’s t-test. (e) Relationship between monocyte CD200R expression and whole 
blood TNF release in response to stimulation with 100 µg PHA. Black line, sarcoidosis linear regression; grey 
line, control linear regression. (f) Stimulated TNF release in CD200Rlow and CD200Rhigh mixed subjects; 
p = 0.19.
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ƪǤ PBMCs (2 × 105 cells) were suspended in 50 µl of FACS block-
ing solution containing antibody (10 µg/ml) and incubated at 4 °C in the dark for 1 hour. Cells were washed and 
resuspended and analysed using a FACSCalibur low cytometer and Cellquest Pro sotware (BD, Oxford, UK). 
Additional analyses were performed using Flowing Sotware 2.5.0 (Perttu Terho). Gates were deined using iso-
type control antibodies.
 ? ? ?Ȁ ? ? ?ǤWhole blood or PBMCs from healthy donors were incubated with anti-
bodies against CD200L, CD200R, or isotype control (10 µg/ml) or PBS for 1 hour at 37 °C, prior to addition of 
100 µg/ml PHA. Supernatants were collected ater 16 hours and stored at −20 °C prior to ELISA.
ƪǤ PBMCs (2 × 105 cells) in 96 well round bot-
tom plates were treated with Brefeldin A to ensure cytokine accumulation for 1–16 hrs. Cells were blocked for 
1 hour, incubated with luorophore-conjugated CD3 or CD14 antibodies for 1 hour on ice, ixed with 4% para-
formaldehyde, permeabilised with ice cold 90% methanol for 30 minutes, and blocked. Intracellular staining with 
directly conjugated IL-6, IL-10, TNF, IFNγ antibodies or isotype control IgG (10 µg/ml) was performed at 4 °C for 
1 hour followed by low cytometric analysis.
Ǥ Sample data were analysed for normality using a D’Agostino and Pearson omnibus 
normality test or Shapiro-Wilk normality test as appropriate. Statistical analyses were performed using GraphPad 
Prism (GraphPad Sotware, La Jolla, USA). Statistical signiicance was determined using Mann-Whitney U, 
Kolmogorov–Smirnov, or Kruskal-Wallis tests for non-parametric distributions and Student’s T-test, one-way 
ANOVA or two-way ANOVA for parametric distributions. Multiple comparisons underwent Sidak, Tukey’s or 
Bonferroni post-hoc analyses as appropriate.
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